Endpoint Ventures

Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.

Shasqi, Inc. is a biopharmaceutical company founded in 2018 and based in San Francisco, California. The company focuses on developing a platform for local drug activation, utilizing bio-orthogonal chemistry to enable localized drug delivery for cancer treatment. This innovative method activates prodrug versions of chemotherapy agents within an injected polymer gel, allowing for targeted treatment directly at the tumor site. By concentrating the drug's action in a specific location, Shasqi's approach aims to minimize side effects and enhance treatment efficacy, allowing healthcare providers to deliver multiple drugs to the tumor more effectively.

Viosera Therapeutics, Inc. is focused on developing therapies to combat antibiotic resistance, particularly targeting methicillin-resistant Staphylococcus aureus (MRSA). Founded in July 2016, the company has its headquarters in Sunnyvale, California, and an additional office in St. Louis, Missouri. Viosera is known for its innovative approach that utilizes artificial intelligence to predict and block the evolution of drug resistance in both cancer and bacterial infections. Its primary product, VT1, is specifically designed to treat MRSA bloodstream infections, allowing healthcare providers to effectively manage and suppress antibiotic resistance, ultimately aiming to enhance patient outcomes.

Synkrino Biotherapeutics is a biotech platform that discovers and develops novel drug targets directly from the immune system of patients. The platform is providing monitoring for pediatric rheumatologists for life-threatening conditions. It is currently building a rapid, portable field test for the RNA virus 2019-nCoV/COVID-19, adapting its existing analytic protocols for community public health screening. Synkrino Biotherapeutics' therapeutics use AI + Immunology Discovery Engine (AIDE Engine) which applies neural networks and machine learning to measure the immune tissue from patients to repeatably discover novel and biologically-valid drug targets, enabling healthcare providers to cure their patients and improve their lives.

HelpWear Inc., founded in 2015 and based in Toronto, Canada, focuses on enhancing at-home healthcare through innovative, affordable products. The company has developed a waterproof heart monitoring wearable device that detects heart attacks and stores cardiovascular data. This device features an embedded emergency contact system that sends real-time alerts to medical facilities, ensuring timely support for patients with heart conditions. HelpWear's approach prioritizes clinical needs, aiming to create solutions that meet both patient and healthcare system requirements, thereby improving the overall management of heart health.

BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.